Neogenix Oncology, Inc. and Cambridge Biomedical Inc. Form a Partnership for Development of Blood Based Cancer Diagnostic Tests  
6/16/2011 8:57:02 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Neogenix Oncology, Inc. is pleased to announce it has signed an agreement with Cambridge Biomedical, Inc, based in Boston, MA, for the development of its pancreatic and colorectal cancer diagnostic serum ELISA assays. Cambridge Biomedical provides core expertise in assay optimization and validation within an FDA recognized laboratory that is CLIA certified and CAP accredited. Neogenix has developed tumor specific biomarkers for the detection of pancreatic and colorectal cancer in tissue and serum. The ELISA assay utilizes the Neogenix patent protected therapeutic monoclonal antibodies (NEO-101, NEO 201, NEO 301) . These diagnostic assays will serve as the companion products for the Neogenix anti-cancer mAb therapeutic pipeline and hold additional hope for early detection of pancreatic and colorectal cancer.